Craig Tendler

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

E O’Brien, Nely Wigler, Moshe Inbar et al. · Annals of Oncology · 2004 · 1.7K citations · Full text

Liposomal Doxorubicin Hcl, Metastatic Breast Cancer, Oncology +8

Transactivation of the transforming growth factor beta 1 (TGF-beta 1) gene by human T lymphotropic virus type 1 tax: a potential mechanism for the increased production of TGF-beta 1 in adult T cell leukemia.

S J Kim, John H. Kehrl, J. D. Burton et al. · The Journal of Experimental Medicine · 1990 · 226 citations · Full text

Cancer-associated Virus, Medicine, T-regulatory Cell +11

Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer

Alan Keller, Robert Mennel, Vassilis A. Georgoulias et al. · Journal of Clinical Oncology · 2004 · 209 citations · Full text

Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.

Philippe Solal‐Céligny, Éric Lepage, Nicole Brousse et al. · Journal of Clinical Oncology · 1998 · 206 citations

Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy.

Craig Tendler, Steven J. Greenberg, W. A. Blattner et al. · Proceedings of the National Academy of Sciences · 1990 · 194 citations

Pathogenic Implications, Spontaneous Proliferation, T-regulatory Cell +19